SORL1 PTV-carriers in this sample had a median AAO of 62 years, 10 years earlier than carriers of wild-type SORL1. Other rare missense variants with MAF < 0.05%, or coding variants with MAF > 0.05% had no or only limited effects on AD risk. This evidence concerns the gene SORL1 and Alzheimer disease.